Boyle, Alan and David Freestone (eds.). International Law and Sustainable Development: Past Achievements and Future Challenges

2000/01/01 by Loren Laine, Kenneth DeVault, Kenneth R. DeVault +8 · 28 citations
Social Sciences · Environmental Science · #Human Rights and Development #World Trade Organization Law #International Environmental Law and Policies

paper · doi:10.1053/j.gastro.2022.09.041

Abstract

Vonoprazan was noninferior and superior to the PPI lansoprazole in healing and maintenance of healing of erosive esophagitis. This benefit was seen predominantly in more severe erosive esophagitis. (ClinicalTrials.gov: NCT04124926).

Citations

• Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
• Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021
• ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease

Cited by

• Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers
• Comparison of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
• Safety of Potassium‐Competitive Acid Blockers Compared With Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease and Peptic Ulcer Disease: A Systematic Review and Meta‐Analysis
• Vonoprazan: A New Potassium-Competitive Acid Blocker. [europepmc]
• Gastroesophageal Reflux Disease in Obesity: Bariatric Surgery as Both the Cause and the Cure in the Morbidly Obese Population. [europepmc]
• Heartburn Relief Is the Major Unmet Need for Drug Development in Gastroesophageal Reflux Disease: Threshold Value Analysis. [europepmc]
• Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). [europepmc]
• Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis. [europepmc]
• Treatment Response With Potassium-competitive Acid Blockers Based on Clinical Phenotypes of Gastroesophageal Reflux Disease: A Systematic Literature Review and Meta-analysis. [europepmc]
• Endoscopic Advances in the Diagnosis and Management of Gastroesophageal Reflux Disease. [europepmc]
• Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. [europepmc]
• Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates. [europepmc]
• Network Meta-Analysis of Comparing Different Dosages of Potassium-Competitive Acid Blocker With Proton-Pump Inhibitor in Acid-Related Disorders. [europepmc]
• Quality indicators for upper GI endoscopy. [europepmc]
• Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/Caspase-1/GSDMD pyroptotic pathway. [europepmc]
• Quality Indicators for Upper GI Endoscopy. [europepmc]
• Potassium-Competitive Acid Blockers and Proton Pump Inhibitors: The Dynamic Duo of Acid Blockers. [europepmc]
• Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial. [europepmc]
• pH Impedance Monitoring on Proton Pump Inhibitor Therapy Impacts Management Decisions in Proven GERD but Not in Unproven GERD. [europepmc]
• Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies. [europepmc]
• Amprenavir Mitigates Pepsin-Induced Transcriptomic Changes in Normal and Precancerous Esophageal Cells. [europepmc]
• Diagnosis and Management of Gastroesophageal Reflux Disease: Current Insights. [europepmc]
• Prescription trends of gastric acid suppressants and association with potential adverse events in Korea: a real-world cross-sectional study. [europepmc]
• Drug treatment strategies for erosive esophagitis in adults: a narrative review. [europepmc]
• Follow-up study of vonoprazan maintenance therapy for reflux esophagitis: A 96-week evaluation in patients with PPI-refractory disease. [europepmc]
• Gastroesophageal reflux disease related to laparoscopic sleeve gastrectomy. [europepmc]
• Proton pump inhibitors are not associated with an increased risk of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials. [europepmc]
• Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors. [europepmc]

Related

• Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
• Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
• Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
• Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders
• Comparison of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials